2Xideas AG Trims Holdings in Halozyme Therapeutics, Inc.

Institutional investor reduces stake in biopharmaceutical company

Mar. 14, 2026 at 7:04am

Got story updates? Submit your updates here. ›

2Xideas AG, an institutional investor, has reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.9% during the third quarter, according to a recent 13F filing with the Securities & Exchange Commission. The firm now owns 158,824 shares of the biopharmaceutical company's stock, making it the 7th largest position in its investment portfolio.

Why it matters

Institutional investors like 2Xideas AG closely monitor and adjust their holdings in publicly traded companies, which can provide insights into the overall market sentiment and performance of specific stocks. Halozyme Therapeutics is a biopharmaceutical company focused on developing novel drug-delivery technologies, and changes in its institutional ownership may signal shifts in investor confidence or strategic priorities.

The details

According to the 13F filing, 2Xideas AG sold 25,722 shares of Halozyme Therapeutics during the third quarter, reducing its total stake to 158,824 shares. The firm's investment in Halozyme Therapeutics now accounts for 2.5% of its overall portfolio, making it the 7th largest position. The filing does not provide specific reasons for the reduction in holdings.

  • The 13F filing covers the third quarter of the year.

The players

2Xideas AG

An institutional investor that manages a portfolio of investments, including a position in Halozyme Therapeutics.

Halozyme Therapeutics, Inc.

A biopharmaceutical company that specializes in the development and commercialization of novel drug-delivery technologies, including its flagship ENHANZE® platform.

Got photos? Submit your photos here. ›

The takeaway

The reduction in 2Xideas AG's holdings in Halozyme Therapeutics may signal a shift in the institutional investor's outlook on the biopharmaceutical company, but it does not necessarily indicate broader market sentiment. Investors and analysts will likely continue to monitor Halozyme's performance and any changes in its institutional ownership to gauge the company's long-term prospects.